Company intelligence / Profile preview

AC BioScience

Epalinges, Vaud, Switzerlandac-bioscience.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 2

Overview

AC BioScience has developed a portfolio of anti-cancer drugs focused on enhancing immune-checkpoint inhibitor therapies and improving drug delivery to hypoxic tumors. Their lead programs include molecules that have shown promising preclinical results in reducing tumor burden and converting non-responder patients into candidates for immunotherapy. The company’s most advanced asset, ACB2003.4, is entering exploratory Phase II trials for metastatic pancreatic cancer; other assets are at preclinical or early clinical stages[1][2][4].

Therapeutic areas: Oncology
Modalities: Small molecules (e.g., ACB2112 in the Azole group)Multikinase inhibitors (e.g., ACB1801)Sphingosine-1 lyase inhibitors (e.g., ACB2003.4)
Industry: Biotech

Drug pipeline

1 asset

ACB2112

Preclinical

Beyond the preview

Go deeper on AC BioScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC BioScience.

Explore the full profile